Common Contracts
2 similar Research Collaboration and Exclusive License Agreement contracts by Sigilon Therapeutics, Inc.
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN SIGILON THERAPEUTICS, INC. and ELI LILLY AND COMPANY April 2, 2018Research Collaboration and Exclusive License Agreement • November 13th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of April 2, 2018 (the “Effective Date”) by and between Sigilon Therapeutics, Inc. (“Sigilon”), a Delaware corporation having a place of business at 100 Binney Street, Suite 600, Cambridge, MA 02142 and Eli Lilly and Company, an Indiana corporation having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Each of Sigilon and Lilly is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN SIGILON THERAPEUTICS, INC. and ELI LILLY AND COMPANY April 2, 2018Research Collaboration and Exclusive License Agreement • August 21st, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of April 2, 2018 (the “Effective Date”) by and between Sigilon Therapeutics, Inc. (“Sigilon”), a Delaware corporation having a place of business at 100 Binney Street, Suite 600, Cambridge, MA 02142 and Eli Lilly and Company, an Indiana corporation having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Each of Sigilon and Lilly is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
